Daptomycin: possibilities and prospectives of administration in clinical practice

Cover Page

Cite item

Full Text

Abstract

Daptomycin is the first representative of the class of cyclic polypeptides, reached the application in clinical practice. Unlike most antibiotics, it has rapid bactericidal activity, including against microbial cells in biofilms. The spectrum of activity of daptomycin includes almost all clinically significant gram(+) bacteria, including strains resistant to other classes of antimicrobials. Currently, in the Russian Federation, daptomycin is registered for two indications: complicated skin and soft tissue infections at a dose of 4 mg/kg 1 time per day and blood flow infections caused by S. aureus, including bacteremia and right-sided endocarditis, at a dose of 6 mg/kg 1 time per day.

About the authors

Andrey I. Danilov

Smolensk State Medical University

Author for correspondence.
Email: dr.DanAndr@yandex.ru

PhD, Assistant, Department of Clinical Pharmacology

Russian Federation, Smolensk

Andrey V. Evseev

Smolensk State Medical University

Email: hypoxia@yandex.ru

Dr Med Sci, Professor, Head, Department of Physiology, Research Center

Russian Federation, Smolensk

Stela G. Fominykh

Omsk State Medical University

Email: dr.DanAndr@yandex.ru

Dr Med Sci, Assistant Professor, Department of Pharmacology, clinical pharmacology

Russian Federation, Omsk

References

  1. Дехнич А.В., Данилов А.И. Даптомицин: обзор фармакологических, клинических и микробиологических параметров // Клиническая фармакология и антимикробная химиотерапия. – 2010. – Т. 12. – № 4. – С. 295–313. [Dekhnich AV, Danilov AI. Daptomycin — the Review of Pharmacological, Clinical and Microbiological Characteristics. Clinical microbiology and antimicrobial chemotherapy. 2010;12(4):295-313. (In Russ.)]
  2. Данилов А.И., Козлов С.Н. Общие принципы антимикробной терапии инфекционного эндокардита // Клиническая фармакология и терапия. – 2019. – Т. 28. – № 2. – С. 57–60. [Danilov AI, Kozlov SN. General principles of antimicrobial therapy of infective endocarditis. Klinicheskaia farmakologiia i terapiia. 2019;28(2):57-60. (In Russ.)]
  3. Попов Д.А., Зубарева Н.А., Дехнич А.В. Обзор доказательных данных по применению даптомицина при грамположительных инфекциях // Клиническая фармакология и антимикробная химиотерапия. – 2016. – Т. 18. – № 4. – С. 270–281. [Popov DA, Zubareva NA, Dekhnich AV. Evidence Based Review on Daptomycin Use in the Treatment of Gram(+) Infections. Clinical microbiology and antimicrobial chemotherapy. 2016;18(4):270-281. (In Russ.)]
  4. Habib G, Lancellotti P, Antunes MJ, et. al. 2015 ESC Guidelines for the management of infective endocarditis: the task force for the management of infective endocarditis of the European society of cardiology (ESC). Eur Heart J. 2015;36(44):3075-3128. https://doi.org/ 10.1093/eurheartj/ehv319.
  5. Wang SZ, Hu JT, Zhang C, et al. The safety and efficacy of daptomycin versus other antibiotics for skin and soft-tissue infections: a meta-analysis of randomised controlled trials. BMJ Open. 2014;4(6):e004744. https://doi.org/ 10.1136/bmjopen-2013-004744.
  6. Liu C, Mao Z, Yang M, et al. Efficacy and safety of daptomycin for skin and soft tissue infections: a systematic review with trial sequential analysis. Ther Clin Risk Manag. 2016;12:1455-1466. https://doi.org/10.2147/TCRM.S115175.
  7. Cogo A, Gonzalez-Ruiz A, Pathan R, Hamed K. Real-World Treatment of Complicated Skin and Soft Tissue Infections with Daptomycin: Results from a Large European Registry (EU-CORE). Infect Dis Ther. 2015;4(3):273-282. https://doi.org/ 10.1007/s40121-015-0074-x.
  8. Zhao M, Liang L, Ji L, et al. Similar efficacy and safety of daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bloodstream infections: a meta-analysis. Int J Antimicrob Agents. 2016;48(3):231-238. https://doi.org/ 10.1016/j.ijantimicag.2016.06.010.
  9. Rangaraj G, Cleveland KO, Gelfand MS. Comparative Analysis of Daptomycin and Vancomycin in the Treatment of Vertebral Osteomyelitis. Infect Dis Clin Pract (Baltim Md). 2013:1. https://doi.org/ 10.1097/ipc.0000000000000116
  10. Malizos K, Sarma J, Seaton RA, et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis. 2016;35(1):111-118. https://doi.org/ 10.1007/s10096-015-2515-6.
  11. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007;22(8):2239-2246. https://doi.org/ 10.1093/ndt/gfm141.
  12. Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673-1681. https://doi.org/ 10.1086/420818.

Copyright (c) 2020 Danilov A.I., Evseev A.V., Fominykh S.G.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).